Long-term follow-up study of TPIP for PH-ILD
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous TPIP study (INS1009-311).
- You cannot have had serious side effects from TPIP in the earlier study that the doctor thinks would make it unsafe to continue.
- You cannot be taking other PAH medications (like prostacyclins, bosentan, ambrisentan, macitentan, or riociguat) except for sildenafil or tadalafil.
- You must have pulmonary hypertension specifically from interstitial lung disease (not from other causes like heart disease, blood clots, or COPD).
- You cannot have left-sided heart failure or heart failure with preserved ejection fraction (HFpEF).
- You must not be allergic or hypersensitive to treprostinil or any ingredient in TPIP (like mannitol or leucine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
This trial tests whether an inhaled medication called treprostinil can improve exercise ability in people with exercise-induced pulmonary hypertension. It aims to see if the drug helps with shortness of breath during activity.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.